{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-24-000002","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.959725+00:00","generated_at":"2026-06-07T04:02:05.785581+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Novocure appoints Dr. Nicolas Leupin as CMO; Pritesh Shah steps down as executive officer","bullets":["Dr. Nicolas Leupin appointed CMO, overseeing medical affairs, safety, and clinical development.","Pritesh Shah resigns as executive officer; to serve as Senior Advisor to CEO through June 30, 2025.","Frank Leonard appointed EVP and President, Novocure Oncology; base salary $525,000, target bonus 60%.","Shah's salary drops from $500k to $120k after June 2024; equity grants continue vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-24-000002","json":"https://secwatch.observer/filing/0001645113-24-000002.json","markdown":"https://secwatch.observer/filing/0001645113-24-000002.md","text":"https://secwatch.observer/filing/0001645113-24-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000002/0001645113-24-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000002/nvcr-20240104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:02:05.785581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"383357b041","claim":"Pritesh Shah resigned as Chief Growth Officer at NovoCure Ltd.","evidence_excerpt":"Effective January 1, 2024, Pritesh Shah, Chief Growth Officer of the Company, resigned his position as an executive officer of the Company and agreed to become a Senior Advisor to the Chief Executive Officer, a non-executive position.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000002/0001645113-24-000002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Growth Officer"}],"fact_type":"executive_change"},{"claim_id":"9d6cfb02c7","claim":"Frank Leonard was appointed as Executive Vice President and President, Novocure Oncology at NovoCure Ltd.","evidence_excerpt":"Effective January 1, 2024, the Company appointed Frank Leonard, Executive Vice President and President, Novocure Oncology.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000002/0001645113-24-000002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and President, Novocure Oncology"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}